Document Type : original article


1 Department of Gastroenterology,Faculty of medicine,Mashhad university of medical sciences,Mashhad,Iran

2 Department of Pediatrics, School of Medicine, Akbar hospital, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Pediatrics, School of Medicine, Antimicrobial Resistance Research Center, Basic Sciences Research Institute, Akbar hospital, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Pediatrics, School of Nursing and Midwifery, Nursing and Midwifery Care Research Center, Akbar hospital, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

6 Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Inflammatory Bowel Disease (IBD) is a multifactorial disease, posing significant challenges to public health. The aim of this study is to determine the effect of silymarin on the symptom severity in pediatric patients with IBD.
Methods & Materials: This randomized clinical trial was conducted on children aged 5-18 diagnosed with IBD referred to the GI clinic at Akbar Children's Hospital in Mashhad. Those who met the inclusion criteria were randomly allocated into either the intervention or placebo group, each group consisting of 20 participants. In the intervention group, silymarin was administered three times daily in divided doses for three months. The control group received a placebo. To assess the efficacy of silymarin, PUCAI and PCDAI were evaluated for all patients at three different time points: before the intervention, during the first visit, and after the intervention. Data were analyzed utilizing the SPSS version 25, with a significance level set at p < 0.05.
Results: The comparison of the disease activity index scores in patients with IBD between the silymarin and placebo groups revealed that during the initial evaluation, no significant difference was observed in the disease activity index score between the two groups before the intervention (p>0.05). However, a statistically significant difference was observed in the disease activity index score between the two groups during the second, and third evaluations (p<0.05).


  1. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL: Harrison's principles of internal medicine. (No Title) 2022.
  2. Kamalian A, Asl MS, Dolatshahi M, Afshari K, Shamshiri S, Roudsari NM, Momtaz S, Rahimi R, Abdollahi M, Abdolghaffari AH: Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways. World Journal of Gastroenterology 2020, 26(24):3365.
  3. Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, Spyckerelle C, Pariente B, Peyrin-Biroulet L, Turck D: Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988–2011): a population-based study of French adolescents. Official journal of the American College of Gastroenterology| ACG 2018, 113(2):265-272.
  4. Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(1):46-54. e42.
  5. Martino G, Caputo A, Schwarz P, Bellone F, Fries W, Quattropani M, Vicario C: Alexithymia and inflammatory bowel disease: a systematic review. Frontiers in psychology 2020, 11:1763.
  6. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P: Psychological issues in inflammatory bowel disease: an overview. Gastroenterology research and practice 2012, 2012.
  7. Feldman M, Friedman LS, Brandt LJ: Sleisenger and Fordtran's gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management: Elsevier health sciences; 2015.
  8. Rosen MJ, Dhawan A, Saeed SA: Inflammatory bowel disease in children and adolescents. JAMA pediatrics 2015, 169(11):1053-1060.
  9. Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G: European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. Journal of Crohn's and Colitis 2019, 13(6):673-685e.
  10. Fabian A, Rutka M, Ferenci T, Bor R, Balint A, Farkas K, Milassin A, Lénárt Z, Nagy F, Szepes Z: The use of complementary and alternative medicine is less frequent in patients with inflammatory bowel disease than in patients with other chronic gastrointestinal disorders. Gastroenterology Research and Practice 2018, 2018.
  11. Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E: Disease impact on the quality of life of children with inflammatory bowel disease. World journal of gastroenterology 2017, 23(6):1067.
  12. Kuenzig ME, Manuel DG, Donelle J, Benchimol EI: Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. Cmaj 2020, 192(45):E1394-E1402.
  13. Burisch J, Munkholm P: The epidemiology of inflammatory bowel disease. Scandinavian journal of gastroenterology 2015, 50(8):942-951.
  14. Jairath V, Feagan BG: Global burden of inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020, 5(1):2-3.
  15. Brown BI: Inflammatory Bowel Disease: Towards a Model for Personalised Nutritional Therapy. 2022.
  16. Waslyk A, Bakovic M: Biological activity and therapeutic potential of quercetin for inflammatory bowel disease. Journal of Food Science and Nutrition Research 2021, 4(2):94-117.
  17. Zarenezhad E, Abdulabbas HT, Kareem AS, Kouhpayeh SA, Barbaresi S, Najafipour S, Mazarzaei A, Sotoudeh M, Ghasemian A: Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review. Archives of Microbiology 2023, 205(6):252.
  18. Khare T, Palakurthi SS, Shah BM, Palakurthi S, Khare S: Natural product-based nanomedicine in treatment of inflammatory bowel disease. International journal of molecular sciences 2020, 21(11):3956.
  19. Malekzadeh MM, Sima A, Alatab S, Sadeghi A, Daryani NE, Adibi P, Maleki I, Vossoughinia H, Fakheri H, Yazdanbod A: Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East. Intest Res 2019, 17(3):330-339.
  20. Alireza Taghavi S, Reza Safarpour A, Hosseini SV, Noroozi H, Safarpour M, Rahimikazerooni S: Epidemiology of inflammatory bowel diseases (IBD) in Iran: a review of 740 patients in Fars Province, Southern Iran. Iranian Journal of Colorectal Research 2013, 1(1):1-2.
  21. Olfatifar M, Zali MR, Pourhoseingholi MA, Balaii H, Ghavami SB, Ivanchuk M, Ivanchuk P, Nazari SH, Shahrokh S, Sabour S: The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study. BMC gastroenterology 2021, 21(1):204.
  22. Hosseini RS, Mansour-Ghanaei F, Shafaghi A, Hojati A, Joukar F, Roushan ZA, Hosseini FA, Mavaddati S: Exacerbation causes among inflammatory bowel disease patients in Guilan Province north of Iran. Journal of Coloproctology (Rio de Janeiro) 2019, 39:138-144.
  23. Cai Z, Wang S, Li J: Treatment of inflammatory bowel disease: a comprehensive review. Frontiers in medicine 2021, 8:765474.
  24. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H: Inflammatory bowel disease: clinical aspects and treatments. Journal of inflammation research 2014:113-120.
  25. Vidal-Lletjós S, Beaumont M, Tomé D, Benamouzig R, Blachier F, Lan A: Dietary protein and amino acid supplementation in inflammatory bowel disease course: what impact on the colonic mucosa? Nutrients 2017, 9(3):310.
  26. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, Yasa N, Khademi Y, Abdollahi M: On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Central European Journal of Biology 2009, 4:204-213.
  27. Rastegarpanah M, Malekzadeh R, Vahedi H, Mohammadi M, Elahi E, Chaharmahali M, Safarnavadeh T, Abdollahi M: A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chinese journal of integrative medicine 2015, 21:902-906.
  28. Fraschini F, Demartini G, Esposti D: Pharmacology of silymarin. Clinical drug investigation 2002, 22:51-65.
  29. Kittur S, Wilasrusmee S, Pedersen WA, Mattson MP, Straube-West K, Wilasrusmee C, Jubelt B, Kittur DS: Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. Journal of Molecular Neuroscience 2002, 18:265-269.
  30. Soleimani V, Delghandi PS, Moallem SA, Karimi G: Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytotherapy research 2019, 33(6):1627-1638.
  31. Malekolkalami M, Behfar M, Tehrani A-A: Effect of short term oral administration of silymarin on healing of colonic anastomosis in rats. Iranian Journal of Veterinary Surgery 2020, 15(2):106-114.
  32. Al-Drees AM, Khalil MS: Histological and immunohistochemical effects of L-arginine and silymarin on TNBS-induced inflammatory bowel disease in rats. 2016.
  33. Mirzaei N, Jahanian Sadatmahalleh S, Rouholamin S, Nasiri M: A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations. Scientific Reports 2022, 12(1):17549.
  34. Jahromi V, Kafilzadeh F, Johari H: The investigation of silymarin effect on colon ulcer induced acetic acid in mice Balb/C. Annals of Biological Research 2012, 3(7):3691-3695.
  35. Malekinejad H, Sheikhzadeh S, Hobbenaghi R: Silymarin attenuates mycophenolate mofetil-induced duodenal disorders in rats. Avicenna Journal of Phytomedicine 2014, 4(3):170.
  36. Takhshid MA RA, Tavasouli AR, Khabaz Z: Protective effects of silymarin on acetic acid–induced colitis in rats. Journal of Mazandaran University of Medical Sciences 2011, 21(84):53-61.